LHNVD-105 shows robust and long-lasting responses via both intramuscular and intradermal administration
Oct. 4, 2023
Synthetic, multi-epitope peptide vaccines are becoming an attractive universal influenza vaccine strategy. Longhorn Vaccines & Diagnostics LLC has created LHNVD-105, an influenza vaccine candidate consisting of unconjugated multi-epitope influenza peptides.